{"title":"OncoDB。糖基因:糖基化相关基因的综合癌症基因组数据库","authors":"Yen-Hsieh Chen, Y. Jou","doi":"10.1109/ICIIBMS.2017.8279701","DOIUrl":null,"url":null,"abstract":"Glycosylation by classic définition is a serial biochemical and enzymatic addition that a glycosyl donor attached to the hydroxyl or functional group of glycosyl acceptor, such as protein or lipid, to form a branch structure. Emerging evidences that aberrant expression of glycosylation-related genes (glycogenes) resulting in altered glycosylation targets have been identified its importance in tumor progression including invasion, migration, proliferation, angiogenesis, and metastasis, while all these components are highly correlated with clinical diagnosis and treatment. To facilitate our understanding of such genes participated in tumor progression, we construct a database OncoDB.Glycogene for developing new theranostic targets of cancers and demonstrate our text-mining based glycogene corpus with the combination of The Cancer Genome Atlas (TCGA) data to draw the interaction between abnormal glycosylation with tumor from integrated genomic viewpoints. We first showed that the coverage of 3026 glycogenes from OncoDB.Glycogene are more comprehensive and unique than other public glycogene resources with inclusion of biosynthesis, metabolism and functional participation of glycosylation such as nucleotide sugar transporter, precursors, or surveillance chaperon, from the aspects of pathway or either Gene Ontology similarity. And to comprehensively reveal glycogenes participated in cancers, we integrated cancer omics data such as copy number, methylation, gene expression with clinical features, i.e. patient survival information, from TCGA with user friendly webpage interfaces for graphic and pathway network displays. With our integrative effort we should improve our knowledge how glycosylation engage in tumor progression and facilitate development of theranostic biomarkers of cancers.","PeriodicalId":122969,"journal":{"name":"2017 International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS)","volume":"50 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"OncoDB. Glycogene: An integrated cancer genomic database for glycosylation-related genes\",\"authors\":\"Yen-Hsieh Chen, Y. Jou\",\"doi\":\"10.1109/ICIIBMS.2017.8279701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glycosylation by classic définition is a serial biochemical and enzymatic addition that a glycosyl donor attached to the hydroxyl or functional group of glycosyl acceptor, such as protein or lipid, to form a branch structure. Emerging evidences that aberrant expression of glycosylation-related genes (glycogenes) resulting in altered glycosylation targets have been identified its importance in tumor progression including invasion, migration, proliferation, angiogenesis, and metastasis, while all these components are highly correlated with clinical diagnosis and treatment. To facilitate our understanding of such genes participated in tumor progression, we construct a database OncoDB.Glycogene for developing new theranostic targets of cancers and demonstrate our text-mining based glycogene corpus with the combination of The Cancer Genome Atlas (TCGA) data to draw the interaction between abnormal glycosylation with tumor from integrated genomic viewpoints. We first showed that the coverage of 3026 glycogenes from OncoDB.Glycogene are more comprehensive and unique than other public glycogene resources with inclusion of biosynthesis, metabolism and functional participation of glycosylation such as nucleotide sugar transporter, precursors, or surveillance chaperon, from the aspects of pathway or either Gene Ontology similarity. And to comprehensively reveal glycogenes participated in cancers, we integrated cancer omics data such as copy number, methylation, gene expression with clinical features, i.e. patient survival information, from TCGA with user friendly webpage interfaces for graphic and pathway network displays. With our integrative effort we should improve our knowledge how glycosylation engage in tumor progression and facilitate development of theranostic biomarkers of cancers.\",\"PeriodicalId\":122969,\"journal\":{\"name\":\"2017 International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS)\",\"volume\":\"50 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"2017 International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1109/ICIIBMS.2017.8279701\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"2017 International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ICIIBMS.2017.8279701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
糖基化是指糖基供体与糖基受体(如蛋白质或脂质)的羟基或官能团相连,形成分支结构的一系列生化和酶的加成作用。越来越多的证据表明,糖基化相关基因(糖基因)的异常表达导致糖基化靶点改变,这在肿瘤的侵袭、迁移、增殖、血管生成和转移等过程中起着重要作用,而所有这些成分都与临床诊断和治疗高度相关。为了更好地了解这些参与肿瘤进展的基因,我们构建了一个数据库OncoDB。结合癌症基因组图谱(the Cancer Genome Atlas, TCGA)数据,展示基于文本挖掘的糖基因语料库,从综合基因组学的角度揭示异常糖基化与肿瘤之间的相互作用。我们首先从OncoDB中发现3026个糖基因的覆盖范围。糖基因包含核苷酸糖转运体、前体或监视伴侣等糖基化的生物合成、代谢和功能参与,无论从途径还是基因本体相似性方面都比其他公共糖基因资源更全面、更独特。为了全面揭示参与癌症的糖基因,我们将TCGA的癌症组学数据(如拷贝数、甲基化、基因表达)与临床特征(即患者生存信息)相结合,并通过友好的网页界面进行图形化和通路网络显示。通过我们的综合努力,我们应该提高我们对糖基化如何参与肿瘤进展的认识,并促进癌症治疗生物标志物的发展。
OncoDB. Glycogene: An integrated cancer genomic database for glycosylation-related genes
Glycosylation by classic définition is a serial biochemical and enzymatic addition that a glycosyl donor attached to the hydroxyl or functional group of glycosyl acceptor, such as protein or lipid, to form a branch structure. Emerging evidences that aberrant expression of glycosylation-related genes (glycogenes) resulting in altered glycosylation targets have been identified its importance in tumor progression including invasion, migration, proliferation, angiogenesis, and metastasis, while all these components are highly correlated with clinical diagnosis and treatment. To facilitate our understanding of such genes participated in tumor progression, we construct a database OncoDB.Glycogene for developing new theranostic targets of cancers and demonstrate our text-mining based glycogene corpus with the combination of The Cancer Genome Atlas (TCGA) data to draw the interaction between abnormal glycosylation with tumor from integrated genomic viewpoints. We first showed that the coverage of 3026 glycogenes from OncoDB.Glycogene are more comprehensive and unique than other public glycogene resources with inclusion of biosynthesis, metabolism and functional participation of glycosylation such as nucleotide sugar transporter, precursors, or surveillance chaperon, from the aspects of pathway or either Gene Ontology similarity. And to comprehensively reveal glycogenes participated in cancers, we integrated cancer omics data such as copy number, methylation, gene expression with clinical features, i.e. patient survival information, from TCGA with user friendly webpage interfaces for graphic and pathway network displays. With our integrative effort we should improve our knowledge how glycosylation engage in tumor progression and facilitate development of theranostic biomarkers of cancers.